Skip to Content

Daclizumab Pregnancy and Breastfeeding Warnings

Daclizumab is also known as: Zenapax

Daclizumab Pregnancy Warnings

Daclizumab has been assigned to pregnancy category C by the FDA. Animal studies have not been conducted. There are no controlled data in human pregnancy. IgG molecules have been reported to cross the placental barrier. Daclizumab should only be given during pregnancy when benefits outweigh risks. It is recommended that women of childbearing potential use effective contraception before beginning daclizumab therapy, during therapy, and for four months after the completion of therapy.

Daclizumab Breastfeeding Warnings

There are no data on the excretion of daclizumab into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions due to daclizumab in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See Also...
